E7 Antibody

What is the E7 protein and why is it important in HPV research?

The E7 protein is a viral oncoprotein produced by human papillomaviruses, particularly high-risk types such as HPV16 and HPV18. E7 plays a crucial role in viral genome replication by driving quiescent cells into the cell cycle, stimulating progression from G1 to S phase. This allows the virus to efficiently utilize the cellular DNA replication machinery for viral genome replication. The E7 protein possesses both transforming and trans-activating activities critical for HPV pathogenesis .

E7 induces the disassembly of the E2F1 transcription factor from RB1 (retinoblastoma protein), leading to transcriptional activation of E2F1-regulated S-phase genes. Additionally, it interferes with host histone deacetylation mediated by HDAC1 and HDAC2, resulting in transcription activation. E7 also inhibits antiviral and antiproliferative functions of host interferon alpha and impairs the ability of TMEM173/STING to sense cytosolic DNA and promote type I interferon production . These oncogenic properties make E7 a critical target for HPV research and therapeutic development.

What types of E7 antibodies are commercially available for research?

Several types of E7 antibodies are available for HPV research, typically targeting E7 proteins from high-risk HPV types like HPV16 and HPV18. These include:

• Mouse monoclonal antibodies: Such as the HPV18 E7 antibody [8E2] (ab100953), suitable for ELISA, immunofluorescence, immunoprecipitation (IP), and Western blot applications .

• Rabbit monoclonal antibodies: Including HPV16 E7 antibody [EPR25814-116], designed for sandwich ELISA applications and available in conjugation-ready formats for fluorochrome, metal isotope, oligonucleotide, and enzyme labeling .

• IgG-specific antibodies: The HPV18 E7 Antibody (F-7) is an IgG1 κ mouse monoclonal antibody that can be used for Western blot, IP, immunofluorescence, and ELISA techniques .

These antibodies may be available in various conjugated forms (HRP, PE, FITC, Alexa Fluor conjugates) to facilitate different detection methods, enhancing their versatility in experimental applications.

How do E7 antibodies differ between HPV16 and HPV18?

E7 antibodies for HPV16 and HPV18 are designed to recognize the E7 protein from their respective viral types with high specificity. The key differences include:

• Target specificity: HPV16 E7 antibodies specifically recognize the E7 protein from HPV16, while HPV18 E7 antibodies target the HPV18 E7 protein. This specificity is crucial because while both HPV16 and HPV18 are high-risk types, they differ in their genomic sequences and have distinct epitopes .

• Applications: While both types of antibodies can be used for similar applications (Western blot, ELISA, etc.), their specific validated applications may differ. For instance, certain HPV16 E7 antibodies might be optimized for sandwich ELISA, while some HPV18 E7 antibodies might perform better in immunofluorescence studies .

• Research context: HPV16 is most commonly associated with cervical cancer and oropharyngeal cancers, while HPV18 is the second most common high-risk type in cervical cancers. The choice between these antibodies should align with the specific HPV type being studied in the research context.

How can E7 antibodies be used to study HPV-related carcinogenesis?

E7 antibodies serve as valuable tools for investigating HPV-related carcinogenesis through several methodological approaches:

• Protein expression analysis: Using Western blot or immunofluorescence with E7 antibodies, researchers can detect and quantify E7 protein expression in cell lines, patient samples, or experimental models. This helps establish the presence and abundance of this oncogenic protein in different contexts .

• Protein-protein interaction studies: Through immunoprecipitation techniques, E7 antibodies can help identify and characterize interactions between E7 and host cellular proteins such as pRB, HDAC1/2, and TMEM173/STING. These interactions are crucial for understanding the molecular mechanisms of HPV-induced carcinogenesis .

• Functional assays: E7 antibodies can be used to neutralize E7 function in experimental settings, allowing researchers to observe the consequences of E7 inhibition on cell proliferation, differentiation, and transformation.

• Biomarker development: As demonstrated in clinical research, monitoring anti-E7 antibody responses in patient serum can serve as a potential biomarker for disease progression and treatment response in HPV-positive cancers. Increasing antibodies to E7 throughout treatment has been correlated with increased cancer recurrence or progression to mortality in head and neck cancer patients .

What are the optimal protocols for Western blot using E7 antibodies?

The optimal Western blot protocol for E7 antibodies typically includes the following methodological considerations:

• Sample preparation:

  • Cell lysate preparation with complete protease inhibitors

  • Protein quantification (Bradford or BCA assay)

  • Sample denaturation in Laemmli buffer with β-mercaptoethanol at 95°C for 5 minutes

• Gel electrophoresis:

  • 12.5-15% SDS-PAGE is recommended due to the relatively small size of E7 proteins (HPV16 E7: ~11 kDa, HPV18 E7: ~12 kDa)

  • Include positive controls (recombinant E7 protein) and negative controls (HPV-negative cell lines)

• Transfer conditions:

  • PVDF or nitrocellulose membranes (0.2 μm pore size recommended for small proteins)

  • Wet transfer at 100V for 1 hour or 30V overnight at 4°C

• Antibody incubation:

  • Blocking with 5% non-fat milk in TBST for 1-2 hours at room temperature

  • Primary antibody dilution (typically 1:1000-1:2000) in blocking buffer overnight at 4°C

  • Secondary antibody (HRP-conjugated) incubation at 1:2000-1:5000 for 1-2 hours at room temperature

• Detection:

  • Enhanced chemiluminescence (ECL) substrate

  • Exposure times should be optimized based on expression levels

This protocol has been validated for detecting E7 protein expression in research settings, as demonstrated in studies using BL21-gold expression systems where a 36 kDa poly-epitopic E7 protein was successfully detected .

How can E7 antibodies be used in immunofluorescence studies of HPV-infected tissues?

For immunofluorescence studies of HPV-infected tissues using E7 antibodies, researchers should follow these methodological guidelines:

• Sample preparation:

  • For cultured cells: Fix with 4% paraformaldehyde for 15 minutes, permeabilize with 0.2% Triton X-100

  • For tissue sections: Use fresh frozen or FFPE (formalin-fixed paraffin-embedded) sections, with appropriate antigen retrieval for the latter (typically citrate buffer pH 6.0 or EDTA buffer pH 9.0)

• Blocking and antibody application:

  • Block with 5-10% normal serum (matching the species of the secondary antibody) with 1% BSA

  • Incubate with primary E7 antibody at optimized dilution (typically 1:100-1:500) overnight at 4°C

  • Wash 3-5 times with PBS

  • Apply fluorophore-conjugated secondary antibody (1:200-1:1000) for 1-2 hours at room temperature in the dark

• Counterstaining and mounting:

  • Nuclear counterstain with DAPI (1:1000)

  • Mount with anti-fade mounting medium

• Imaging considerations:

  • Use appropriate filter sets for the selected fluorophores

  • Capture z-stacks for thicker tissue sections

  • Include positive controls (known HPV-positive cells) and negative controls (primary antibody omission)

• Analysis:

  • Evaluate E7 localization (typically nuclear and cytoplasmic)

  • Quantify signal intensity in different cellular compartments

  • Compare expression patterns between different stages of HPV-related lesions

This approach allows for spatial visualization of E7 protein expression and localization within infected cells and tissues, providing insights into the distribution of viral oncoproteins during HPV-related disease progression.

How are E7 antibodies used in HPV vaccine development research?

E7 antibodies play critical roles in HPV vaccine development research through several sophisticated applications:

• Immunogen validation: Researchers use E7 antibodies to verify the expression and conformation of E7 antigens in candidate vaccines. This ensures that the vaccine constructs properly express the intended epitopes necessary for stimulating appropriate immune responses .

• Epitope mapping: E7 antibodies help identify and characterize specific immunogenic epitopes within the E7 protein. This information guides the design of multi-epitopic vaccines that incorporate both MHC class I-restricted epitopes (for CD8+ T cells) and MHC class II-restricted epitopes (for CD4+ T cells), as demonstrated in recent vaccine development studies .

• Immune response assessment: Following vaccination in experimental models, E7 antibodies are used in ELISA assays to quantify the development of anti-E7 antibody responses. In one study, flat-bottom 96-well Maxisorp microtiter plates were coated with purified multi-epitopic E7 vaccine (MEVE7) at 5 μg/mL, and mouse sera from vaccinated animals were tested to evaluate the humoral immune response .

• Therapeutic efficacy monitoring: In therapeutic vaccine studies targeting existing HPV infections, E7 antibodies help monitor changes in E7 expression in infected tissues following vaccination, providing insights into the potential clearance of HPV-infected cells.

• Production and purification of vaccine antigens: Anti-E7 antibodies, particularly those targeting his-tag fusion proteins, are instrumental in confirming the expression and purifying recombinant E7 proteins from prokaryotic expression systems, as evidenced in recent prokaryotic expression systems utilizing BL21-gold E. coli strains .

What is the significance of E7 antibody serology in monitoring HPV-associated cancer patients?

E7 antibody serology has emerged as a potentially valuable tool for monitoring patients with HPV-associated cancers, with significant clinical implications:

• Predictive biomarker potential: Research has demonstrated that increasing antibodies to E7 throughout treatment correlates with increased cancer recurrence or progression to mortality in HPV-positive head and neck cancer (HNC) patients. This trend showed 100% specificity as a predictive test in one study, suggesting its utility in identifying patients at higher risk of treatment failure .

• Longitudinal monitoring: Serial serum specimens from HPV-positive cancer patients can be evaluated for anti-E7 antibody levels. In a study of 48 HPV-positive HNC patients, 45.8% were positive for high-risk anti-E7 at one or more collection time points during the study period, with positivity defined as +3 standard deviations above the mean of p16-negative patients' ELISA values .

• Treatment response assessment: While E7 positivity at the first visit was not useful in predicting recurrence and survival (p = 1), patients who had positive trending high-risk anti-E7 throughout the study were more likely to have worse clinical outcomes with cancer relapse or progression to mortality (p = .004) .

• Complementary to existing biomarkers: E7 antibody serology can complement other biomarkers such as p16 immunohistochemistry. In some studies, patients without p16 positivity typically had negative anti-E7 values, consistent with the absence of high-risk HPV infection .

• Non-invasive monitoring: As a serum-based test, E7 antibody serology offers a non-invasive approach to monitoring HPV-positive cancer patients, potentially reducing the need for repeated biopsies while providing valuable prognostic information.

How can E7 antibodies be used to study the molecular mechanisms of HPV-induced oncogenesis?

E7 antibodies enable researchers to investigate the molecular mechanisms of HPV-induced oncogenesis through several sophisticated experimental approaches:

• Chromatin immunoprecipitation (ChIP): E7 antibodies can be used in ChIP assays to identify genomic regions where E7 affects transcription factor binding or chromatin modifications. This helps elucidate how E7 alters the epigenetic landscape to promote cell proliferation and oncogenesis.

• Proximity ligation assays (PLA): These assays utilize E7 antibodies to visualize and quantify protein-protein interactions in situ, allowing researchers to study how E7 interacts with cellular proteins like pRB, HDACs, and E2F in their native cellular context.

• Immunoprecipitation-mass spectrometry (IP-MS): E7 antibodies can be used to immunoprecipitate E7 protein complexes from cells, followed by mass spectrometry analysis to identify novel interacting partners, providing comprehensive insights into E7's oncogenic mechanism .

• STING pathway analysis: Recent research has revealed that E7 interacts with host TMEM173/STING to impair its ability to sense cytosolic DNA and promote type I interferon production. E7 antibodies can help characterize this interaction and its consequences for immune evasion during HPV infection .

• Cell cycle regulation studies: Using E7 antibodies in combination with cell cycle markers (e.g., cyclins, CDKs), researchers can investigate how E7 disrupts normal cell cycle control, particularly how it induces the disassembly of E2F1 from RB1, leading to inappropriate S-phase entry .

What are the common challenges in optimizing E7 antibody-based ELISA assays?

Researchers frequently encounter several challenges when optimizing ELISA assays using E7 antibodies, along with potential solutions:

• Sensitivity limitations:

  • Challenge: Detecting low levels of E7 protein or anti-E7 antibodies in clinical samples

  • Solution: Implement signal amplification systems (e.g., biotin-streptavidin), optimize antibody concentrations, and extend substrate incubation times under controlled conditions

• Specificity concerns:

  • Challenge: Cross-reactivity between different HPV types due to sequence homology between E7 proteins

  • Solution: Use type-specific E7 antibodies with validated specificity; include appropriate controls with recombinant E7 proteins from different HPV types to verify specificity

• Standardization issues:

  • Challenge: Establishing appropriate cut-off values for positivity in serological assays

  • Solution: Include control sera from HPV-negative individuals and define positivity as +3 standard deviations above the mean of negative controls, as demonstrated in clinical studies

• Protocol optimization:

  • For coating: Use purified recombinant E7 protein at 5 μg/mL in phosphate-buffered saline (pH 7.4), incubated overnight at 4°C

  • For blocking: Apply 3% (w/v) skimmed milk in PBST (PBS containing 0.05% v/v Tween-20)

  • For detection: Utilize HRP-conjugated secondary antibodies at 1:1000 dilution with tetramethylbenzidine (TMB) substrate solution and measure optical density at 450 nm with 630 nm as reference wavelength

• Sample preparation considerations:

  • For serum samples: Heat-inactivate at 56°C for 30 minutes, centrifuge to remove particulates, and store aliquots at -80°C to avoid freeze-thaw cycles

  • For cell/tissue lysates: Use appropriate lysis buffers with protease inhibitors and determine optimal protein concentration for coating

How can researchers troubleshoot non-specific binding issues with E7 antibodies in immunohistochemistry?

Non-specific binding is a common challenge when using E7 antibodies in immunohistochemistry. Here are methodological approaches to troubleshoot and overcome these issues:

• Optimizing blocking conditions:

  • Use a combination of serum (5-10%) from the same species as the secondary antibody, plus 1-3% BSA

  • Consider adding 0.1-0.3% Triton X-100 to the blocking solution to reduce hydrophobic interactions

  • Explore alternative blocking agents such as casein or commercial blocking reagents specifically designed for immunohistochemistry

• Antibody validation and titration:

  • Perform careful titration experiments (1:50 to 1:1000 dilutions) to determine the optimal antibody concentration

  • Include appropriate positive controls (HPV-positive cell lines) and negative controls (primary antibody omission, isotype controls, and HPV-negative tissues)

  • Consider using monoclonal antibodies like HPV18 E7 Antibody (F-7) or HPV16 E7 antibody [EPR25814-116] which may offer higher specificity than polyclonal alternatives

• Antigen retrieval optimization:

  • Compare different antigen retrieval methods (heat-induced epitope retrieval using citrate buffer pH 6.0 vs. EDTA buffer pH 9.0)

  • Optimize retrieval times (10-30 minutes) and methods (microwave, pressure cooker, or water bath)

• Background reduction strategies:

  • Pre-absorb antibodies with tissue powder from negative samples

  • Include avidin/biotin blocking steps when using biotin-based detection systems

  • Apply 0.3% hydrogen peroxide in methanol before antibody incubation to block endogenous peroxidase activity

  • Use Sudan Black B (0.1-0.3%) to reduce autofluorescence when performing immunofluorescence

• Detection system considerations:

  • Evaluate polymer-based detection systems which can offer improved signal-to-noise ratios

  • Consider tyramide signal amplification for detecting low-abundance targets while maintaining specificity

What are the best practices for quantifying E7 protein expression using Western blot and E7 antibodies?

Quantifying E7 protein expression via Western blot requires careful methodology to ensure accurate and reproducible results:

• Sample preparation standardization:

  • Extract proteins using consistent lysis buffers containing protease inhibitors

  • Quantify total protein using reliable methods (BCA or Bradford assay)

  • Load equal amounts of protein (typically 20-50 μg) per lane

  • Include recombinant E7 protein standards at known concentrations for quantitative analysis

• Electrophoresis and transfer optimization:

  • Use 12.5-15% SDS-PAGE gels for optimal resolution of the relatively small E7 proteins

  • Implement wet transfer protocols to ensure efficient transfer of small proteins

  • Verify transfer efficiency using reversible protein stains (Ponceau S) before immunoblotting

• Antibody selection and validation:

  • Choose well-characterized antibodies like mouse monoclonal HPV18 E7 antibody [8E2] or HPV18 E7 Antibody (F-7) for Western blot applications

  • Validate antibody specificity using positive controls (HPV-positive cell lines) and negative controls (HPV-negative cell lines)

• Normalization strategies:

  • Always probe for housekeeping proteins (β-actin, GAPDH, or α-tubulin) as loading controls

  • Consider the use of total protein normalization methods (e.g., stain-free technology) as an alternative to single housekeeping proteins

  • Ensure the linear dynamic range of detection for both E7 and housekeeping proteins

• Quantification methodology:

  • Use densitometry software to quantify band intensities (e.g., ImageJ, Image Lab)

  • Subtract background signal appropriately

  • Express results as the ratio of E7 to loading control

  • For absolute quantification, generate a standard curve using recombinant E7 protein

• Technical replication:

  • Perform at least three independent biological replicates

  • Include technical replicates within each experiment

  • Apply appropriate statistical analysis to determine significance of observed differences

How might E7 antibodies contribute to developing novel therapeutic approaches for HPV-associated cancers?

E7 antibodies hold significant potential for advancing novel therapeutic approaches for HPV-associated cancers through several innovative strategies:

• Antibody-drug conjugates (ADCs):

  • E7 antibodies could be conjugated to cytotoxic drugs, specifically targeting HPV-infected cells while sparing normal tissues

  • This approach leverages the specificity of E7 antibodies to deliver therapeutic payloads directly to cancer cells expressing the E7 protein

• Bispecific antibody development:

  • Engineering bispecific antibodies that simultaneously target E7 and immune cell receptors (e.g., CD3 on T cells)

  • This approach could redirect cytotoxic T cells to attack HPV-infected cells expressing E7 protein on their surface or presenting E7 peptides via MHC

• Therapeutic vaccine enhancement:

  • E7 antibodies can help validate the epitope selection and expression in multi-epitopic vaccine designs

  • Recent research on E7 multi-epitopic vaccines (MEVE7) incorporating both CD4+ and CD8+ T cell epitopes shows promising results in preclinical models

  • These vaccines could be optimized for expression in prokaryotic systems, as demonstrated with bacterial expression systems like BL21-gold E. coli strains

• Immune response monitoring:

  • Using E7 antibodies to track immune responses to therapeutic interventions

  • Anti-E7 antibody trends during treatment have shown value as potential biomarkers for treatment response and disease outcomes in head and neck cancers

• Combination therapy approaches:

  • E7 antibody-based therapies could be combined with immune checkpoint inhibitors to enhance anti-tumor immunity

  • The specificity of E7-targeted approaches could complement the broader immune activation strategies of checkpoint blockade

What emerging technologies are enhancing the utility of E7 antibodies in HPV research?

Several cutting-edge technologies are expanding the applications and enhancing the utility of E7 antibodies in HPV research:

• Single-cell analysis techniques:

  • Single-cell proteomics platforms allow researchers to examine E7 expression at the individual cell level within heterogeneous tumor samples

  • Mass cytometry (CyTOF) incorporating E7 antibodies enables simultaneous detection of E7 expression alongside dozens of other cellular markers

• Multiplex imaging systems:

  • Cyclic immunofluorescence and multiplexed ion beam imaging (MIBI) facilitate visualization of E7 expression in spatial context with other cellular markers

  • These approaches reveal the tumor microenvironment surrounding E7-expressing cells, providing insights into immune cell interactions

• Liquid biopsy applications:

  • Circulating tumor cell (CTC) analysis using E7 antibodies enables non-invasive monitoring of HPV-positive cancer cells in blood

  • Cell-free HPV DNA detection complemented with anti-E7 antibody serology offers comprehensive liquid biopsy approaches

• CRISPR-based functional genomics:

  • CRISPR screens combined with E7 antibody-based detection systems help identify genes that modulate E7 expression or function

  • This approach reveals potential new therapeutic targets in the HPV oncogenesis pathway

• Advanced recombinant antibody engineering:

  • Development of high-affinity recombinant antibody fragments (scFvs, Fabs) against E7 for improved imaging and therapeutic applications

  • Nanobodies against E7 protein that offer superior tissue penetration for both imaging and therapeutic applications

• Artificial intelligence integration:

  • Machine learning algorithms applied to E7 antibody-based tissue imaging help identify subtle expression patterns associated with disease progression

  • These computational approaches may reveal previously unrecognized correlations between E7 expression patterns and clinical outcomes

How can researchers better standardize E7 antibody-based assays for clinical applications?

Standardization of E7 antibody-based assays for clinical applications requires systematic approaches to ensure reliability, reproducibility, and clinical utility:

• Reference standard development:

  • Establish internationally recognized reference proteins and antibodies for E7 detection

  • Create standardized recombinant E7 proteins representing major high-risk HPV types (HPV16, HPV18, etc.) with defined purity and activity specifications

  • Develop reference panels of sera with known anti-E7 antibody titers for calibrating serological assays

• Protocol harmonization:

  • Design robust standard operating procedures (SOPs) that specify detailed methodological parameters:

    • For ELISA: antigen coating concentration (5 μg/mL), blocking conditions (3% skim milk), antibody dilutions, and incubation times

    • For Western blot: protein extraction methods, gel composition (12.5% SDS-PAGE), transfer conditions, and detection systems

  • Implement proficiency testing programs across laboratories to assess consistency

• Analytical validation guidelines:

  • Establish consensus criteria for:

    • Limit of detection (LOD) and limit of quantification (LOQ)

    • Analytical specificity, including cross-reactivity testing with related HPV types

    • Reproducibility requirements (intra-assay and inter-assay coefficients of variation <10-15%)

    • Minimum sensitivity and specificity requirements for clinical applications

• Clinical validation approaches:

  • Develop standardized definitions of clinical positivity (e.g., +3 standard deviations above control mean)

  • Correlate assay results with clinical outcomes in large, well-characterized patient cohorts

  • Determine appropriate cut-off values for specific clinical applications (diagnosis, prognosis, or treatment monitoring)

• Quality control measures:

  • Implement regular quality control testing using characterized samples

  • Incorporate internal controls in each assay run

  • Develop digital imaging standards for immunohistochemistry and immunofluorescence applications

  • Establish external quality assessment programs for laboratories performing E7 antibody-based testing

• Data reporting standardization:

  • Create uniform reporting templates that include all relevant technical parameters

  • Develop consensus guidelines for interpreting and reporting results in research and clinical settings

  • Establish centralized databases for aggregating standardized E7 antibody assay results to facilitate meta-analyses